{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:54:22Z","timestamp":1793415262309,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Sinunasal symptoms and chronic rhinusinutitis are common in patients with cystic fibrosis. Cystic fibrosis transmembrane regulator (CFTR) modulators have led to dramatic improvements of respiratory symptoms and quality of life in patients with cystic fibrosis. This study aims to evaluate subjective and objective sinunasal symptoms after start of CFTR-modulator\u00a0triple therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>43 patients (<jats:italic>n<\/jats:italic>\u2009=\u20096\u2009&lt;\u200918\u00a0years), treated with highly effective CFTR-modulator therapy with elexacaftor\u2013tezacaftor\u2013ivacaftor (ELX\/TEZ\/IVA) were included, as were 20 controls with cystic fibrosis but without CFTR-modulator therapy (<jats:italic>n<\/jats:italic>\u2009=\u20096\u2009&lt;\u200918\u00a0years). All assessed their sinunasal symptoms retrospectively and the intervention group\u00a0at a mean of 9.3 (2\u201316) months after start of ELX\/TEZ\/IVA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Improvements in SNOT-22 overall score from <jats:italic>m<\/jats:italic>\u2009=\u200932.7 to <jats:italic>m<\/jats:italic>\u2009=\u200915.7 points (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) as well in the nasal, emotional, otologic, and sleep subdomains could be demonstrated in the intervention group. No changes were found in the control group. Children showed lower SNOT-22 scores than adults and a reduction of SNOT-22 total score from <jats:italic>m<\/jats:italic>\u2009=\u20099.4 to <jats:italic>m<\/jats:italic>\u2009=\u20092.2 (<jats:italic>p<\/jats:italic>\u2009=\u20090.25) was found. 8 patients were evaluated by an otorhinolaryngologist before and after start of ELX\/TEZ\/IVA and showed pronounced objective clinical improvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Highly effective CFTR-modulator therapy has a significant positive impact on both subjective and objective sinunasal symptoms in patients with CF and some improvement could be demonstrated in children\u2009&lt;\u200918\u00a0years as well.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00405-023-07859-4","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T14:02:45Z","timestamp":1675519365000},"page":"3271-3277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effects of CFTR-modulator triple therapy on sinunasal symptoms in children and adults with cystic fibrosis"],"prefix":"10.1007","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7217-3312","authenticated-orcid":false,"given":"Sebastian F. N.","family":"Bode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Rapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Lienert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorit","family":"Fabricius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"issue":"1","key":"7859_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00405-021-06875-6","volume":"279","author":"J Krajewska","year":"2022","unstructured":"Krajewska J, Zub K, Slowikowski A, Zatonski T (2022) Chronic rhinosinusitis in cystic fibrosis: a review of therapeutic options. Eur Arch Otorhinolaryngol 279(1):1\u201324. https:\/\/doi.org\/10.1007\/s00405-021-06875-6","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"12","key":"7859_CR2","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/thx.2008.112870","volume":"64","author":"MR Loebinger","year":"2009","unstructured":"Loebinger MR, Bilton D, Wilson R (2009) Upper airway 2: bronchiectasis, cystic fibrosis and sinusitis. Thorax 64(12):1096\u20131101. https:\/\/doi.org\/10.1136\/thx.2008.112870","journal-title":"Thorax"},{"issue":"8","key":"7859_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1097\/00005537-199608000-00018","volume":"106","author":"VG Gentile","year":"1996","unstructured":"Gentile VG, Isaacson G (1996) Patterns of sinusitis in cystic fibrosis. Laryngoscope 106(8):1005\u20131009. https:\/\/doi.org\/10.1097\/00005537-199608000-00018","journal-title":"Laryngoscope"},{"key":"7859_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/00034894211045636","author":"S Leong","year":"2021","unstructured":"Leong S, Sharma RK, Safi C, DiMango E, Keating C, Gudis DA, Overdevest JB (2021) Association of quality of life measures and otolaryngologic care in cystic fibrosis patients. Ann Otol Rhinol Laryngol. https:\/\/doi.org\/10.1177\/00034894211045636","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"6","key":"7859_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/1099-0496(200012)30:6<481::aid-ppul8>3.0.co;2-n","volume":"30","author":"C Gysin","year":"2000","unstructured":"Gysin C, Alothman GA, Papsin BC (2000) Sinonasal disease in cystic fibrosis: clinical characteristics, diagnosis, and management. Pediatr Pulmonol 30(6):481\u2013489. https:\/\/doi.org\/10.1002\/1099-0496(200012)30:6%3c481::aid-ppul8%3e3.0.co;2-n","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"7859_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jcf.2010.01.001","volume":"9","author":"HJ Bonestroo","year":"2010","unstructured":"Bonestroo HJ, de Winter-de Groot KM, van der Ent CK, Arets HG (2010) Upper and lower airway cultures in children with cystic fibrosis: do not neglect the upper airways. J Cyst Fibros 9(2):130\u2013134. https:\/\/doi.org\/10.1016\/j.jcf.2010.01.001","journal-title":"J Cyst Fibros"},{"key":"7859_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012979.pub3","volume":"4","author":"TK Karanth","year":"2022","unstructured":"Karanth TK, Karanth V, Ward BK, Woodworth BA, Karanth L (2022) Medical interventions for chronic rhinosinusitis in cystic fibrosis. Cochrane Database Syst Rev 4:CD012979. https:\/\/doi.org\/10.1002\/14651858.CD012979.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"7859_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22953","author":"DB Spielman","year":"2021","unstructured":"Spielman DB, Beswick DM, Kimple AJ, Senior BA, Aanaes K, Woodworth BA, Schlosser RJ, Lee S, Cho DY, Adappa ND et al (2021) The management of cystic fibrosis chronic rhinosinusitis: an evidenced-based review with recommendations. Int Forum Allergy Rhinol. https:\/\/doi.org\/10.1002\/alr.22953","journal-title":"Int Forum Allergy Rhinol"},{"issue":"10212","key":"7859_CR9","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM et al (2019) Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394(10212):1940\u20131948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet"},{"issue":"19","key":"7859_CR10","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F et al (2019) Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 381(19):1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","journal-title":"N Engl J Med"},{"issue":"4","key":"7859_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1164\/rccm.201403-0595IM","volume":"190","author":"D Hayes Jr","year":"2014","unstructured":"Hayes D Jr, McCoy KS, Sheikh SI (2014) Improvement of sinus disease in cystic fibrosis with ivacaftor therapy. Am J Respir Crit Care Med 190(4):468. https:\/\/doi.org\/10.1164\/rccm.201403-0595IM","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"7859_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/coa.12310","volume":"40","author":"SI Sheikh","year":"2015","unstructured":"Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D Jr (2015) Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation. Clin Otolaryngol 40(1):16\u201321. https:\/\/doi.org\/10.1111\/coa.12310","journal-title":"Clin Otolaryngol"},{"issue":"3","key":"7859_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jcf.2014.07.013","volume":"14","author":"CL Vreede","year":"2015","unstructured":"Vreede CL, Berkhout MC, Sprij AJ, Fokkens WJ, Heijerman HG (2015) Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508\/S1215N. J Cyst Fibros 14(3):412\u2013413. https:\/\/doi.org\/10.1016\/j.jcf.2014.07.013","journal-title":"J Cyst Fibros"},{"issue":"3","key":"7859_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/alr.22251","volume":"9","author":"J McCormick","year":"2019","unstructured":"McCormick J, Cho DY, Lampkin B, Richman J, Hathorne H, Rowe SM, Woodworth BA (2019) Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients. Int Forum Allergy Rhinol 9(3):292\u2013297. https:\/\/doi.org\/10.1002\/alr.22251","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"7859_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA et al (2015) Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373(3):220\u2013231. https:\/\/doi.org\/10.1056\/NEJMoa1409547","journal-title":"N Engl J Med"},{"issue":"17","key":"7859_CR16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E et al (2018) VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med 379(17):1612\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1807120","journal-title":"N Engl J Med"},{"issue":"5","key":"7859_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","volume":"205","author":"SY Graeber","year":"2022","unstructured":"Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, Drescher M, Minso R, Ringshausen FC, Rueckes-Nilges C et al (2022) Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles. Am J Respir Crit Care Med 205(5):540\u2013549. https:\/\/doi.org\/10.1164\/rccm.202110-2249OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"7859_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","volume":"20","author":"E DiMango","year":"2021","unstructured":"DiMango E, Overdevest J, Keating C, Francis SF, Dansky D, Gudis D (2021) Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis. J Cyst Fibros 20(3):460\u2013463. https:\/\/doi.org\/10.1016\/j.jcf.2020.07.002","journal-title":"J Cyst Fibros"},{"issue":"2","key":"7859_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/alr.22716","volume":"11","author":"JE Douglas","year":"2021","unstructured":"Douglas JE, Civantos AM, Locke TB, Sweis AM, Hadjiliadis D, Hong G, Dorgan DJ, Kohanski MA, Palmer JN, Adappa ND (2021) Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis. Int Forum Allergy Rhinol 11(2):201\u2013203. https:\/\/doi.org\/10.1002\/alr.22716","journal-title":"Int Forum Allergy Rhinol"},{"key":"7859_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.06.003","author":"S Shakir","year":"2022","unstructured":"Shakir S, Echevarria C, Doe S, Brodlie M, Ward C, Bourke SJ (2022) Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and sinonasal symptoms in advanced cystic fibrosis. J Cyst Fibros. https:\/\/doi.org\/10.1016\/j.jcf.2022.06.003","journal-title":"J Cyst Fibros"},{"issue":"1","key":"7859_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","volume":"19","author":"DM Beswick","year":"2022","unstructured":"Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Lynch DA, Taylor-Cousar JL (2022) Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient-reported outcomes. Ann Am Thorac Soc 19(1):12\u201319. https:\/\/doi.org\/10.1513\/AnnalsATS.202101-057OC","journal-title":"Ann Am Thorac Soc"},{"key":"7859_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.03.011","author":"L Wucherpfennig","year":"2022","unstructured":"Wucherpfennig L, Triphan SMF, Wege S, Kauczor HU, Heussel CP, Schmitt N, Wuennemann F, Mayer VL, Sommerburg O, Mall MA et al (2022) Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor\/tezacaftor\/ivacaftor therapy in adults with cystic fibrosis. J Cyst Fibros. https:\/\/doi.org\/10.1016\/j.jcf.2022.03.011","journal-title":"J Cyst Fibros"},{"issue":"5","key":"7859_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","volume":"34","author":"C Hopkins","year":"2009","unstructured":"Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP (2009) Psychometric validity of the 22-item sinonasal outcome test. Clin Otolaryngol 34(5):447\u2013454. https:\/\/doi.org\/10.1111\/j.1749-4486.2009.01995.x","journal-title":"Clin Otolaryngol"},{"key":"7859_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2020.110316","volume":"140","author":"D Riedl","year":"2021","unstructured":"Riedl D, Dejaco D, Steinbichler TB, Innerhofer V, Gottfried T, Bektic-Tadic L, Giotakis AI, Rumpold G, Riechelmann H (2021) Assessment of health-related quality-of-life in patients with chronic Rhinosinusitis - Validation of the German Sino-Nasal Outcome Test-22 (German-SNOT-22). J Psychosom Res. 140:110316. https:\/\/doi.org\/10.1016\/j.jpsychores.2020.110316","journal-title":"J Psychosom Res."},{"issue":"5","key":"7859_CR25","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00405-019-05320-z","volume":"276","author":"D Dejaco","year":"2019","unstructured":"Dejaco D, Riedl D, Huber A, Moschen R, Giotakis AI, Bektic-Tadic L, Steinbichler T, Kahler P, Riechelmann H (2019) The SNOT-22 factorial structure in European patients with chronic rhinosinusitis: new clinical insights. Eur Arch Otorhinolaryngol 276(5):1355\u20131365. https:\/\/doi.org\/10.1007\/s00405-019-05320-z","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"7859_CR26","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.jcf.2021.09.014","volume":"21","author":"DM Beswick","year":"2022","unstructured":"Beswick DM, Humphries SM, Balkissoon CD, Strand M, Vladar EK, Ramakrishnan VR, Taylor-Cousar JL (2022) Olfactory dysfunction in cystic fibrosis: impact of CFTR modulator therapy. J Cyst Fibros 21(2):e141\u2013e147. https:\/\/doi.org\/10.1016\/j.jcf.2021.09.014","journal-title":"J Cyst Fibros"},{"key":"7859_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22974","author":"AJ Kimple","year":"2022","unstructured":"Kimple AJ, Senior BA, Naureckas ET, Gudis DA, Meyer T, Hempstead SE, Resnick HE, Albon D, Barfield W, Benoit MM et al (2022) Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations. Int Forum Allergy Rhinol. https:\/\/doi.org\/10.1002\/alr.22974","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-023-07859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-023-07859-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-023-07859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T11:09:05Z","timestamp":1685099345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-023-07859-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["7859"],"URL":"https:\/\/doi.org\/10.1007\/s00405-023-07859-4","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,4]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}